DexComの空売り状況は、投資家がDexComの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

DexCom (NASDAQ:DXCM) 株価情報, 空売り情報

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Equities

News

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

DexCom Inc

DEXCOM ORD

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 14.45% on an annualized basis producing an average annual return of 26.36%. Currently, DexCom has a market capitalization of $27.15 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $3,262.77 today based on a price of $67.76 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $346,714, and 3 are calls, for a total amount of $110,992.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $100.0 for DexCom, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for DexCom options trades today is 476.12 with a total volume of 901.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for DexCom's big money trades within a strike price range of $50.0 to $100.0 over the last 30 days.
<h3>DexCom 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727381809_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$6.8</td>
<td>$6.5</td>
<td>$6.6</td>
<td>$55.00</td>
<td>$165.0K</td>
<td>0</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.3</td>
<td>$12.1</td>
<td>$12.3</td>
<td>$70.00</td>
<td>$71.3K</td>
<td>471</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$75.00</td>
<td>$50.4K</td>
<td>645</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.6</td>
<td>$15.2</td>
<td>$15.44</td>
<td>$70.00</td>
<td>$30.8K</td>
<td>73</td>
<td style="text-align: right;">21</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$2.75</td>
<td>$2.7</td>
<td>$2.72</td>
<td>$60.00</td>
<td>$29.9K</td>
<td>1.0K</td>
<td style="text-align: right;">146</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
After a thorough review of the options trading surrounding DexCom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of DexCom</h3>
<ul>
<li>With a volume of 3,204,425, the price of DXCM is up 1.2% at $67.53. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

What the Options Market Tells Us About DexCom

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 25%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $176,999, and 4 are calls, for a total amount of $148,385.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for DexCom, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 890.12, with a total volume reaching 1,305.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $55.0 to $75.0, throughout the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726678146_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.8</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$65.00</td>
<td>$62.6K</td>
<td>929</td>
<td style="text-align: right;">271</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$65.00</td>
<td>$59.9K</td>
<td>1.1K</td>
<td style="text-align: right;">548</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$10.3</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$75.00</td>
<td>$44.8K</td>
<td>617</td>
<td style="text-align: right;">45</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.8</td>
<td>$7.5</td>
<td>$7.7</td>
<td>$55.00</td>
<td>$39.2K</td>
<td>122</td>
<td style="text-align: right;">54</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.8</td>
<td>$70.00</td>
<td>$35.1K</td>
<td>1.3K</td>
<td style="text-align: right;">45</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
After a thorough review of the options trading surrounding DexCom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>DexCom's Current Market Status</h3>
<ul>
<li>With a volume of 1,428,567, the price of DXCM is up 1.31% at $69.84. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>Expert Opinions on DexCom</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $95.0.
<ul>
<li>An analyst from Piper Sandler downgraded its action to Overweight with a price target of $90. </li>
<li>An analyst from Stifel persists with their Buy rating on DexCom, maintaining a target price of $100. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in DexCom

<ul>
<li>While in orbit, the Polaris Dawn crew will conduct scientific research designed to advance both human health on Earth and our understanding of human health during long-duration spaceflights. Given that one in ten1 people globally live with diabetes, it's essential to understand the impact of space travel on human health to ensure it is accessible and inclusive of all people, including those living with diabetes and other chronic health conditions.</li>
<li>Over their five days in space, the Polaris Dawn crew will conduct around 40 scientific experiments, including several to better understand the effects of spaceflight on glucose health. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.labfront.com%2F&amp;esheet=54114343&amp;newsitemid=20240827030657&amp;lan=en-US&amp;anchor=Labfront&amp;index=2&amp;md5=5af47c319ca2d55c537a7a0f4992a874">Labfront</a>, a platform assisting health researchers in collecting and analyzing physiological data, is collaborating with Dexcom to provide advanced analytics for the data collected using Dexcom CGM. The research will explore how microgravity, fluid shifts, and blood flow restriction exercises impact glucose regulation.</li>
</ul>

Health Care

General

DexCom Announced The Dexcom G6 Continuous Glucose Monitoring System Is Being Worn By Astronauts In Space As Part Of The Polaris Dawn Mission

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 15.25% on an annualized basis producing an average annual return of 26.82%. Currently, DexCom has a market capitalization of $28.42 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $3,460.00 today based on a price of $70.93 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725899411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he prefers Royal Caribbean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) over Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) .
&#8220;Royal Caribbean has the best systems right now, it's got the best numbers. It's the one you want, not Carnival,&#8221; he added.
On Aug. 27, Carnival unveiled new itineraries for seven ships sailing in 2026 and 2027 from Miami, Port Canaveral, Galveston, and Baltimore.
EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) has been<a href="https://www.benzinga.com/quote/EPR/earnings"> &#8220;too rocky&#8221; for Cramer.</a> On July 31, EPR Properties posted better-than-expected sales for its second quarter.
Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) is &#8220;too inconsistent,&#8221; Cramer said. &#8220;They don't get my buy with that level of inconsistency.&#8221;
On Aug. 19, Whirlpool declared a quarterly dividend of $1.75 per share on its common stock.
When asked about DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), he said, &#8220;I did not really care for that last quarter or the explanation of why things had slowed.&#8221;
On Aug. 26, Piper Sandler analyst Matt O&#8217;Brien reiterated DexCom with an Overweight rating and maintained a $90 price target.
The &#8220;Mad Money&#8221; host said he really liked SpartanNash Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>). &#8220;I like that dividend,&#8221; he added.
On Aug. 15, SpartanNash reported second-quarter adjusted earnings per share of 59 cents, beating the street view of 56 cents. Quarterly revenues of $2.23 billion missed the analyst consensus of $2.27 billion.
Price Action:
<ul>
<li>EPR Properties shares fell 0.5% to settle at $47.72 on Thursday.</li>
<li>Carnival shares closed at $16.15 during Thursday's session.</li>
<li>Whirlpool shares fell 1.3% to close at $97.53 during Thursday's session.</li>
<li>Dexcom shares fell 1.1% to settle at $69.05 on Thursday.</li>
<li>SpartanNash shares fell 1.9% to settle at $22.12 during the session.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>
Image: Shutterstock

Long Ideas

Travel

Media

SPTN

Jim Cramer Doesn't Like Carnival Right Now: Royal Caribbean Is 'The One You Want'

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 55%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $213,146, and 3 are calls, for a total amount of $154,020.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $135.0 for DexCom over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 567.88, with a total volume reaching 2,675.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $65.0 to $135.0, throughout the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725393656_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.9</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$70.00</td>
<td>$96.9K</td>
<td>438</td>
<td>224</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$0.95</td>
<td>$0.55</td>
<td>$0.89</td>
<td>$70.00</td>
<td>$56.4K</td>
<td>2.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$62.9</td>
<td>$61.8</td>
<td>$62.41</td>
<td>$135.00</td>
<td>$37.4K</td>
<td>37</td>
<td>6</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$0.95</td>
<td>$0.85</td>
<td>$0.85</td>
<td>$70.00</td>
<td>$36.8K</td>
<td>2.0K</td>
<td>439</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.5</td>
<td>$10.4</td>
<td>$10.5</td>
<td>$70.00</td>
<td>$31.5K</td>
<td>339</td>
<td>5</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Following our analysis of the options activities associated with DexCom, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 3,961,087, the DXCM's price is up by 4.3%, now at $72.33. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 51 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $90.66666666666667.
<ul>
<li>Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for DexCom, targeting a price of $82. </li>
<li>In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $90. </li>
<li>An analyst from Stifel persists with their Buy rating on DexCom, maintaining a target price of $100. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on DexCom: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 63%, bearish.
Out of all of the options we uncovered, 10 are puts, for a total amount of $606,156, and there was 1 call, for a total amount of $391,000.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $75.0 for DexCom during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 398.14, with a total volume reaching 11,462.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $60.0 to $75.0, throughout the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725036408_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$4.7</td>
<td>$4.5</td>
<td>$4.6</td>
<td>$75.00</td>
<td>$390.9K</td>
<td style="text-align: right;">544</td>
<td>861</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$1.65</td>
<td>$0.9</td>
<td>$1.55</td>
<td>$70.00</td>
<td>$132.8K</td>
<td style="text-align: right;">105</td>
<td>857</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.8</td>
<td>$60.00</td>
<td>$80.9K</td>
<td style="text-align: right;">593</td>
<td>89</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/06/24</td>
<td>$1.7</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$69.00</td>
<td>$62.4K</td>
<td style="text-align: right;">394</td>
<td>54</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$2.3</td>
<td>$2.1</td>
<td>$2.25</td>
<td>$70.00</td>
<td>$56.2K</td>
<td style="text-align: right;">105</td>
<td>2.5K</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Having examined the options trading patterns of DexCom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 1,665,804, the DXCM's price is up by 0.3%, now at $69.83. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 55 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $90.66666666666667.
<ul>
<li>In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $90. </li>
<li>An analyst from Baird has decided to maintain their Neutral rating on DexCom, which currently sits at a price target of $82. </li>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for DexCom, targeting a price of $100. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DexCom Unusual Options Activity For August 30

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 15.18% on an annualized basis producing an average annual return of 27.38%. Currently, DexCom has a market capitalization of $29.14 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $37,830.95 today based on a price of $72.73 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724781611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $38,000 Today

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and maintains $90 price target.

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on DexCom, Maintains $90 Price Target

In March, the FDA approved DexCom Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) Stelo Glucose Biosensor System as the first over-the-counter (OTC) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys" target="_blank" rel="noreferrer noopener">continuous glucose monitor (CGM)</a>. 
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for people 18 and older who do not use insulin.
On Monday, DexCom announced Stelo is now available for purchase without a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40547929/stelo-by-dexcom-the-first-over-the-counter-glucose-biosensor-in-the-u-s-is-now-available" rel="noreferrer noopener">prescription&nbsp;at&nbsp;Stelo.com</a>.
Stelo is a small biosensor worn on the back of the upper arm.
It is specifically designed to provide the 125 million Americans&nbsp;with Type 2 diabetes who are not using insulin and those with&nbsp;prediabetes with personalized glucose insights sent directly to their smartphones.
These insights reveal how food, exercise, and sleep can affect glucose—all without painful fingersticks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39861919/abbott-labs-makes-marketing-push-for-new-glucose-monitors-targets-health-conscious-consumers" rel="noreferrer noopener">Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers</a>.
Users can buy a one-month supply online for $99 (for a single pack of two sensors (total wear time up to 30 days) or sign up for an ongoing subscription at $89 a month.
In June, the FDA approved two new over-the-counter continuous glucose monitoring (CGM) systems from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): Lingo and Libre Rio. These systems are based on Abbott&#8217;s FreeStyle Libre technology, which is now used by about <a href="https://www.benzinga.com/pressreleases/24/06/n39248164/abbott-receives-u-s-fda-clearance-for-two-new-over-the-counter-continuous-glucose-monitoring-syste" target="_blank" rel="noreferrer noopener">6 million people globally</a>.
Reuters noted that Lingo has been available in Britain since January for $152-$190 (120-150 pounds) per month.
Jake Leach, chief operating officer at Dexcom, told CNBC in an <a href="https://www.cnbc.com/2024/08/26/dexcom-launches-stelo-its-first-over-the-counter-continuous-glucose-monitor.html" target="_blank" rel="noreferrer noopener">interview</a> that Dexcom is working with Amazon to fulfill Stelo deliveries.
Dexcom said patients also have the option to use their flexible spending accounts and health savings accounts to pay for Stelo, CNBC noted.
Stelo is a small, gray device worn on the upper arm, about the size of a quarter and half an inch thick, with a 15-day lifespan before needing replacement. It wirelessly transmits data to a smartphone app, where users specify whether they have Type 2 diabetes, prediabetes, or neither. This information sets a &#8220;Target Range&#8221; for maintaining optimal glucose levels.
Price Action: DXCM stock is up 0.48% at $74.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40553848/baker-hughes-says-us-oil-and-gas-rig-count-declines-for-second-week-report" target="_blank" rel="noreferrer noopener">Baker Hughes Says US Oil And Gas Rig Count Declines For Second Week: Report</a></li>
</ul>
Photo: Shutterstock

Large Cap

Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients

<ul>
<li>Available for purchase today at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stelo.com%2F&amp;esheet=54113088&amp;newsitemid=20240826019839&amp;lan=en-US&amp;anchor=Stelo.com&amp;index=1&amp;md5=88ec3e10c5b5ed9720b0313dc0d9d3b3">Stelo.com</a> for people in the U.S. 18 and older not using insulin</li>
<li>Provides 24/7 powerful and personalized glucose insights directly to a smartphone,&#x2A; revealing how food, exercise and sleep can affect glucose</li>
<li>Tracking glucose just got easier, with no prescription and no fingersticks, ever</li>
<li>Specifically designed to help people with Type 2 diabetes not using insulin and those with prediabetes reach their A1c goals and potentially slow the progression of diabetes.†,1-3</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54113088&amp;newsitemid=20240826019839&amp;lan=en-US&amp;anchor=DexCom&amp;index=2&amp;md5=28c454b72f7497850576697e9d205572">DexCom</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription4 at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stelo.com%2F&amp;esheet=54113088&amp;newsitemid=20240826019839&amp;lan=en-US&amp;anchor=Stelo.com&amp;index=3&amp;md5=9d7cfb8954a62f0aed2c095b05181991">Stelo.com</a>.

Biotech

Reported Earlier, Dexcom Announces Stelo, The First Over-The-Counter Glucose Biosensor In The U.S., Is Now Available For Purchase Without A Prescription

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $104.22, a high estimate of $145.00, and a low estimate of $75.00. A 24.99% drop is evident in the current average compared to the previous average price target of $138.94. 
<img src="https://www.benzinga.com/files/images/story/2024/1724414501_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to DexCom. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DexCom's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of DexCom's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Discovering DexCom: A Closer Look</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>DexCom's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 15.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: DexCom's net margin excels beyond industry benchmarks, reaching 14.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): DexCom's ROE stands out, surpassing industry averages. With an impressive ROE of 6.13%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 2.16%. This signifies efficient management of assets and strong financial health.
Debt Management: DexCom's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 18 Analyst Evaluations For DexCom

Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $90 to $100.

Stifel Maintains Buy on DexCom, Raises Price Target to $100

After eight consecutive positive sessions, Wall Street hit a pause. The S&amp;P 500 and Nasdaq 100 indices ended Tuesday&#8217;s session with slight declines, halting their best winning streaks since May 2024 <a href="https://www.benzinga.com/markets/equities/24/08/40450395/s-p-500-nasdaq-100-extend-8-session-winning-streak-as-wall-street-jitters-go-poof-mondays-key-st">and October 2023, respectively.</a>
The day was characterized by a lack of economic data, leading to a significant drop in trading volumes across major U.S. stock exchanges. 
Fed Governor Michelle Bowman delivered hawkish comments in the afternoon, stating that she still sees upside risks to inflation. This did little to improve an already negative session.
Bowman further emphasized that wage gains remain above the pace consistent with the Fed's inflation goal, and stressed the need to remain vigilant on the price-stability side of the Fed&#8217;s mandate while monitoring risks of a material weakening in the labor market.
<h3 class="wp-block-heading">Tuesday&#8217;s Major Drags On S&amp;P 500, Nasdaq 100</h3>
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed down 0.2%. A similar drop was observed in the tech-heavy Nasdaq 100 index, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
Sector performance saw three sectors finishing in positive territory and eight in the red:
<ul>
<li>The Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) rose 0.5% </li>
<li>Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) rose 0.4%</li>
<li>The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) edged up by 0.1%.</li>
</ul>
On the downside, energy stocks led the laggards as WTI oil prices fell below $74 per barrel, marking a two-week low. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) dropped 2.6%.
Among individual stocks, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was the biggest drag on the S&amp;P 500, falling 2.1% and accounting for a 0.15 percentage point loss in the overall index. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) was another significant negative contributor, falling 3.4% and shaving off 0.04 percentage points from the S&amp;P 500 performance. 
The worst performers in the S&amp;P 500 were Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) and DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), which plunged 6.9% and 6.3%, respectively.
In the Nasdaq 100, Nvidia weighed down the index by 0.18 percentage points, followed by Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), which contributed to a 0.05 percentage point loss. The tech index&#8217;s worst performers were DexCom and China&#8217;s PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), the latter dropping 4.6%.
<h3 class="wp-block-heading">Tuesday&#8217;s Worst Contributors To The S&amp;P 500 Performance</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Weight (%)</td>
<td>1-day return (%)</td>
<td>Contribution</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>6.78</td>
<td>-2.14%</td>
<td>-0.15pp</td>
</tr>
<tr>
<td>Exxon Mobil Corporation</td>
<td>1.13</td>
<td>-3.35</td>
<td>-0.04pp</td>
</tr>
<tr>
<td>Broadcom Inc.</td>
<td>1.55</td>
<td>-1.05</td>
<td>-0.02pp</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Tuesday&#8217;s Worst-Performing S&amp;P 500 Stocks</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Insulet Corporation</td>
<td>-6.88</td>
</tr>
<tr>
<td>DexCom, Inc.</td>
<td>-6.27</td>
</tr>
<tr>
<td>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>)</td>
<td>-5.00</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Tuesday&#8217;s Worst Contributors To The Nasdaq 100 Performance</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Weight (%)</td>
<td>1-day return (%)</td>
<td>Contribution</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>8.26</td>
<td>-2.14</td>
<td>-0.18pp</td>
</tr>
<tr>
<td>Broadcom Inc.</td>
<td>5.18</td>
<td>-1.05</td>
<td>-0.05pp</td>
</tr>
<tr>
<td>PDD Holdings Inc.</td>
<td>0.67</td>
<td>-4.55</td>
<td>-0.03pp</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Tuesday&#8217;s Worst-Performing Nasdaq 100 Stocks</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>DexCom, Inc.</td>
<td>-6.27</td>
</tr>
<tr>
<td>PDD Holdings Inc.</td>
<td>-4.55</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>-3.35</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40466528/jackson-hole-preview-5-important-questions-ahead-of-jerome-powells-fed-speech">Jackson Hole Preview: 5 Important Questions Ahead Of Jerome Powell&#8217;s Fed Speech</a></li>
</ul>

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Econ #s

Federal Reserve

Tech

ETFs

AVGO

MRNA

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PODD

XLRE

S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?

WIIM

Shares of diabetes-related stocks closed lower following data from Lilly showing weekly Tirzepatide injections reduced the risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity.

The S&amp;P 500 and Nasdaq 100 extended their upward streak on Monday, both logging a robust eight consecutive sessions in positive territory as traders maintain optimism about the U.S. economic outlook and improving financial conditions ahead of the Federal Reserve&#8217;s <a href="https://www.benzinga.com/topic/interest-rates">anticipated rate-cut cycle.</a>
For the S&amp;P 500, this marks its longest winning streak since May 2024, while the tech-heavy Nasdaq 100 hasn&#8217;t seen such a run since October 2023.
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed Monday&#8217;s session up 0.95%, bringing it within just 1% of its all-time high reached in mid-July. Nearly 95% of S&amp;P 500 companies have reported second-quarter results. FactSet data shows that 79% of these firms have exceeded earnings-per-share (EPS) expectations, and 60% have posted higher-than-expected revenue. The S&amp;P 500's blended year-over-year earnings growth rate is at 10.9%, the strongest since Q4 2021.
The Nasdaq 100, monitored through the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), closed 1.3% higher, but it remains 4.6 percentage points below its record highs. 
&#8220;Last week saw unfounded US recession fears and global financial market jitters go poof as quickly as they arrived,&#8221; wrote veteran Wall Street investor Ed Yardeni in a note Monday. 
Monday&#8217;s session saw no economic data releases, but investors responded positively to comments from Minneapolis Federal Reserve President Neel Kashkari, a well-known hawk, who hinted at the possibility of a rate cut in September during an exclusive interview with The Wall Street Journal.
Market-implied probabilities currently indicate a 77.5% chance of a 25-basis-point rate cut in September, with a 22.5% likelihood of a larger 50-basis-point cut, according to CME Group FedWatch tool. 
This week, traders will be closely watching key monetary policy discussions at <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40446287/investors-look-for-clues-on-september-rate-cut-at-jackson-hole-how-does-stock-mar">the Jackson Hole Symposium</a>, scheduled for Aug. 22-24, where Fed Chair Jerome Powell is set to speak on Friday at 10 a.m.
&#8220;If the Fed eases too much and doesn't push back against expectations of more rate cuts to come, the yen could strengthen again, triggering a second wave of unwinding carry trades,&#8221; Yardeni warned. 
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</td>
<td>4.93</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>4.52</td>
</tr>
<tr>
<td>Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)</td>
<td>4.41</td>
</tr>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>4.31</td>
</tr>
<tr>
<td>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>4.31</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Nasdaq 100&#8217;s Top Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc.</td>
<td>4.52</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>4.31</td>
</tr>
<tr>
<td>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>4.25</td>
</tr>
<tr>
<td>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</td>
<td>4.10</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>3.62</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40439485/goldman-sachs-cuts-us-recession-odds-to-20-reverses-earlier-increase-as-economic-">Goldman Sachs Cuts US Recession Odds To 20%, Reverses Earlier Increase As Economic Data Improves</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Economics

ILMN

S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers

Deep-pocketed investors have adopted a bullish approach towards DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DXCM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 25 extraordinary options activities for DexCom. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 64% leaning bullish and 28% bearish. Among these notable options, 10 are puts, totaling $511,287, and 15 are calls, amounting to $955,878.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $95.0 for DexCom, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for DexCom options trades today is 442.25 with a total volume of 3,823.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for DexCom's big money trades within a strike price range of $50.0 to $95.0 over the last 30 days.
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724098526_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$12.7</td>
<td>$12.1</td>
<td>$12.7</td>
<td>$70.00</td>
<td>$123.1K</td>
<td style="text-align: right;">426</td>
<td>103</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.9</td>
<td>$10.6</td>
<td>$10.6</td>
<td>$75.00</td>
<td>$106.0K</td>
<td style="text-align: right;">187</td>
<td>100</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$1.0</td>
<td>$0.9</td>
<td>$1.0</td>
<td>$85.00</td>
<td>$100.0K</td>
<td style="text-align: right;">732</td>
<td>1.1K</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/30/24</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$70.00</td>
<td>$98.0K</td>
<td style="text-align: right;">501</td>
<td>340</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.7</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$95.00</td>
<td>$91.8K</td>
<td style="text-align: right;">28</td>
<td>230</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>DexCom's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,557,952, the price of DXCM is up by 4.07%, reaching $77.69.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $97.4.
<ul>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for DexCom, targeting a price of $113. </li>
<li>An analyst from Morgan Stanley persists with their Equal-Weight rating on DexCom, maintaining a target price of $75. </li>
<li>Maintaining their stance, an analyst from BTIG continues to hold a Buy rating for DexCom, targeting a price of $120. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for DexCom, targeting a price of $90. </li>
<li>An analyst from Canaccord Genuity has decided to maintain their Buy rating on DexCom, which currently sits at a price target of $89. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Decoding DexCom's Options Activity: What's the Big Picture?

The S&amp;P 500 and Nasdaq 100 indices notched their seventh consecutive day of gains on Friday, culminating in their strongest weekly performance since late October 2023 as investor sentiment toward risk assets improved in response to a string of upbeat economic indicators <a href="https://www.benzinga.com/calendars/economic">released throughout the week.</a>
Tracking these indices, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) closed with modest daily gains of 0.2% and 0.1%, respectively. For the week, the S&amp;P 500 and Nasdaq 100 soared 4% and 5.5%, marking their best weekly performances in 10 months.
The Dow Jones Index, as tracked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), closed 0.2% higher, marking its fourth straight session of gains and the best week since December 2023.
<h3 class="wp-block-heading">Wall Street Extends Winning Streak On Bullish Economic Data, Record-High Earnings</h3>
On Friday, traders welcomed a better-than-expected consumer sentiment reading from the University of Michigan, which signaled <a href="https://www.benzinga.com/news/econ-s/24/08/40419637/us-consumer-confidence-rebounds-in-august-expectations-are-subject-to-change-as-presidential-campaig">growing optimism among consumers.</a>
A day earlier, initial jobless claims for the week ending Aug. 10 surprised to the downside, indicating fewer concerns about the resilience of the labor market, while retail sales spiked more than expected by 1% on a month-over-month basis in July, marking the strongest month since January 2023.
Softer-than-anticipated inflation data for both consumers and producers released earlier this week further fueled market enthusiasm, cementing expectations for an interest rate cut from the Federal Reserve next month.
The upbeat data has tempered bets on a larger rate reduction, with market participants now leaning toward a more modest 25-basis-point cut. Market-implied probabilities for a larger 50-basis-point reduction have tumbled to 23%, according to CME Group&#8217;s FedWatch tool, as economic data signals no rush for <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40405406/interest-rate-markets-rethink-fed-strategy-as-economic-data-signals-no-rush-for-m">an overly loose monetary policy. </a>
&#8220;The latest data support our view that betting against consumers when jobs are expanding is a bad bet. Even bad weather didn&#8217;t stop them from going to the malls last month,&#8221; said Ed Yardeni, president at Yardeni Research.
The latest earnings season provides no indication of an impending recession, Yardeni said. With over 90% of S&amp;P 500 companies having reported second-quarter results, collective operating earnings per share for the index surged 10.9% year-over-year to a record high of $60.19.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Movers On Friday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)</td>
<td>3.21</td>
</tr>
<tr>
<td>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</td>
<td>3.16</td>
</tr>
<tr>
<td>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)</td>
<td>3.06</td>
</tr>
<tr>
<td>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</td>
<td>2.67</td>
</tr>
<tr>
<td>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</td>
<td>2.47</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Nasdaq 100&#8217;s Top 5 Movers On Friday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Security Name</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)</td>
<td>5.05</td>
</tr>
<tr>
<td>DexCom, Inc.</td>
<td>3.16</td>
</tr>
<tr>
<td>PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)</td>
<td>2.90</td>
</tr>
<tr>
<td>Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)</td>
<td>2.43</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>2.36</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40399595/bill-ackman-cuts-chipotle-stake-right-before-stock-drop-did-billionaire-see-what-the-market-coul">Bill Ackman Cuts Chipotle Stake Right Before Stock Drop: Did Billionaire See What The Market Couldn&#8217;t?</a></li>
</ul>
Photo generated using artificial intelligence via MidJourney.

BBWI

CSCO

SPDR Dow Jones Industrial Average ETF Trust

TEAM

TTWO

ULTA

S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTRS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>4.8K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$530.00</td>
<td>$167.9K</td>
<td>4.3K</td>
<td>2.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$57.50</td>
<td>$25.1K</td>
<td>2.5K</td>
<td>843</td>
</tr>
<tr>
<td>ZBH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$110.00</td>
<td>$56.2K</td>
<td>172</td>
<td>786</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$320.00</td>
<td>$142.5K</td>
<td>879</td>
<td>505</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$185.00</td>
<td>$140.0K</td>
<td>750</td>
<td>218</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$80.2K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>ZVRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$6.00</td>
<td>$46.5K</td>
<td>3</td>
<td>90</td>
</tr>
<tr>
<td>GSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$47.00</td>
<td>$38.4K</td>
<td>3</td>
<td>62</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$75.00</td>
<td>$38.1K</td>
<td>151</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VTRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), we notice a call option sweep that happens to be bullish, expiring in 155 day(s) on January 17, 2025. This event was a transfer of 1361 contract(s) at a $13.00 strike. This particular call needed to be split into 62 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $50.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4856 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with bullish sentiment. It expires in 36 day(s) on September 20, 2024. Parties traded 2099 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $167.9K, with a price of $80.0 per contract. There were 4314 open contracts at this strike prior to today, and today 2102 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 64 day(s) on October 18, 2024. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.1K, with a price of $253.0 per contract. There were 2515 open contracts at this strike prior to today, and today 843 contract(s) were bought and sold. 
• For ZBH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), we notice a put option sweep that happens to be bearish, expiring in 36 day(s) on September 20, 2024. This event was a transfer of 205 contract(s) at a $110.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $56.2K, with a price of $275.0 per contract. There were 172 open contracts at this strike prior to today, and today 786 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with neutral sentiment. It expires in 36 day(s) on September 20, 2024. Parties traded 216 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $142.5K, with a price of $660.0 per contract. There were 879 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a put option sweep with bearish sentiment. It expires in 155 day(s) on January 17, 2025. Parties traded 203 contract(s) at a $185.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $140.0K, with a price of $690.0 per contract. There were 750 open contracts at this strike prior to today, and today 218 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with neutral sentiment. It expires in 190 day(s) on February 21, 2025. Parties traded 200 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $80.2K, with a price of $401.0 per contract. There were 0 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For ZVRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>), we notice a call option sweep that happens to be bullish, expiring in 36 day(s) on September 20, 2024. This event was a transfer of 300 contract(s) at a $6.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $46.5K, with a price of $155.0 per contract. There were 3 open contracts at this strike prior to today, and today 90 contract(s) were bought and sold. 
• Regarding GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), we observe a put option sweep with bearish sentiment. It expires in 190 day(s) on February 21, 2025. Parties traded 62 contract(s) at a $47.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $38.4K, with a price of $620.0 per contract. There were 3 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a call option trade with bearish sentiment. It expires in 127 day(s) on December 20, 2024. Parties traded 57 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $38.1K, with a price of $670.0 per contract. There were 151 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

AMGN

DOCS

VRTX

VTRS

ZVRA

10 Health Care Stocks With Whale Alerts In Today's Session

TCW Select Equities Fund Q2 2024 Commentary

How is QQQ stock faring? The Invesco QQQ ETF is up 0.17% in the past five days and has risen about 19.37% year-to-date. &nbsp; According to TipRank...

QQQ ETF Update, 9/30/2024

Hartford MidCap Fund Q2 2024 Commentary

How is SPY stock faring? The SPDR S&P 500 ETF Trust  is down 0.03% in the past 5 days but has risen about 21.4% year-to-date. According to TipRanks...

SPY ETF Update, 1/10/2024

Warning: DXCM is at high risk of performing badly

A class action lawsuit was filed against DexCom, Inc. ($DXCM) by Levi & Korsinsky on August 21, 2024. The plaintiffs (shareholders) alleged that th...

Class Action Lawsuit Against DexCom, Inc. (NASDAQ:DXCM)

Top movers as S&P 500 clocks another quarter of growth

Top movers as S&P 500 clocks another quarter of record growth

How is VOO stock faring? The Vanguard S&P 500 ETF is down 0.76% in the past five days but has risen 35.68% over the past year.  According to TipRan...

VOO ETF Update, 10/2/2024

Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3

ALLE

APLS

ASML

AXON

BIIB

BKNG

BLDR

CBRE

CDNS

CRWD

CYBR

DDOG

DJIA

DKNG

DLTR

ERIE

EXAS

EXPD

FTNT

GOOG

GOOGL

INTC

LRCX

MPWR

PLTR

SCHW

SHOP

SMCI

SOLV

TRGP

VEEV

Screenshot 2024-10-03 at 5.30.47 PM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

DexCom (DXCM) Accused of Misleading Investors About Sales Force Changes and Financial Outlook - Hagens Berman

Legal

DXCM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

DXCM Deadline Approaching on October 21, 2024: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Class Action Lawsuit Deadline

Faruqi & Faruqi Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

DXCM LITIGATION ALERT: DexCom, Inc. Investors are Notified to Contact BFA Law before Imminent October 21 Deadline in Securities Fraud Class Action (Nasdaq:DXCM)

DXCM SHAREHOLDER ALERT:  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc.

Comments

DexCom

空売り

DexCom (NASDAQ:DXCM) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル